MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company headquartered in New York. The company focuses on discovering, developing, and manufacturing gene therapies for patients with severe diseases, including ocular, neurodegenerative, and salivary gland disorders. Its clinical pipeline includes treatments for inherited retinal diseases, Parkinson's disease, and radiation-induced xerostomia. MeiraGTx is distinctive for its proprietary riboswitch gene regulation platform, which allows for precise control over gene expression using small molecules, and its in-house manufacturing capabilities. The company operates research and manufacturing facilities in the United States and Europe, and collaborates with major pharmaceutical companies like Johnson & Johnson and Sanofi to advance its therapeutic candidates.
